Aerogen Reduces ED admissions by 32%

*Significant impacts also found to discharge rates and median length of stay*

Aerogen, the global leader in aerosol drug delivery, recently announced the results of a ground breaking study which showed a 32% reduction in the number of patients admitted to the hospital when treated with Aerogen® Solo vibrating mesh technology. This breakthrough study demonstrates the impact of a high performance aerosol drug delivery system on patient care in the Emergency Department at St John’s Medical Center (Detroit, Michigan) and was presented simultaneously at both the American Association of Respiratory Care (San Antonio) and the American College of Emergency Physicians (Las Vegas).

The findings come at a time when Emergency Departments across the country are experiencing a sharp increase in the number of patients presenting with respiratory disorders such as COPD, asthma and influenza, which have more frequent exacerbations over the winter season. The result is pressure on hospitals to increase the number of patients going through the Emergency Department.

“Reducing a patient’s need to be admitted means a couple of things. First, it means that patient feels a lot better and is ready to go home, which is great for the patient, but second, it also means one less person who may be waiting for a bed and spending some time in the hospital” noted principal investigator and study co-author Robert Dunne, MD, Vice Chair of Emergency Medicine at St. John Medical Center.

The study looked at 1,576 patients over two sequential 30-day periods in a busy, urban emergency department. It compared the impact of bronchodilator medication administered with Aerogen® Solo vibrating mesh technology to treatments administered with a traditional small volume nebulizer. The research found that Aerogen technology was statistically associated with 32% fewer admissions to the hospital, a 75% reduction in the amount of medication administered and a 37-minute median reduction in the length of a patient’s stay in the Emergency Department.

“This large clinical study demonstrates the impact Aerogen technology can have in the Emergency Department and is further evidence of the outstanding clinical results we’ve seen when Aerogen technology is used in critical medical units all over the world,” noted John Power, Managing Director and CEO of Aerogen. “When patients feel better and can go home faster, without an extended hospital stay, it benefits everyone. This is truly great news for patients, clinicians and hospital administrators alike.”

www.aerogen.com